{"preliminary_commentary":{"by_channel":{"x_thread":6,"youtube":1,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT02858921\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":null,"indication":"BRAF V600-mutant resectable stage III melanoma","name":"NeoTrio","nct_id":"NCT02858921","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=neotrio-nct02858921. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"Neo Trio","arms":[{"description":"Dabrafenib 150mg orally twice a day + Trametinib 2mg orally once a day for 1 week, then followed by treatment with Pembrolizumab 2mg/kg delivered intravenously at weeks 1, 3, and 6, then once every 3 weeks from week 6 for 46 weeks.","label":"Sequential D + T, THEN Pembrolizumab","type":"EXPERIMENTAL"},{"description":"Dabrafenib 150mg orally twice a day + Trametinib 2mg orally once a day + Pembrolizumab 200mg intravenously once every 3 weeks for 6 weeks, the Pembrolizumab alone for 46 weeks","label":"Concurrent D + T AND Pembrolizumab","type":"EXPERIMENTAL"},{"description":"Pembrolizumab 200mg intravenously once every 3 weeks alone for 52 weeks.","label":"Pembrolizumab ONLY","type":"EXPERIMENTAL"}],"collaborators":["Merck Sharp & Dohme LLC","Novartis"],"completion_date":{"date":"2027-11","type":"ESTIMATED"},"conditions":["Melanoma"],"enrollment":{"count":60,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Dabrafenib","otherNames":["Tafinlar"],"type":"DRUG"},{"name":"Trametinib","otherNames":["Mekinist"],"type":"DRUG"},{"name":"Pembrolizumab","otherNames":["Keytruda"],"type":"DRUG"}],"last_update":"2026-08-24","lead_sponsor":"Melanoma Institute Australia","official_title":"A Phase II, Randomised, Open Label Study of Neoadjuvant Dabrafenib, Trametinib and / or Pembrolizumab in BRAF V600 Mutant Resectable Stage IIIB/C/D (Excluding In-transit) Melanoma","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2022-01-02","type":"ACTUAL"},"primary_outcomes":[{"measure":"Pathological Response Rate","timeFrame":"From baseline to 6 weeks"}],"references":[{"citation":"Long GV, Carlino MS, Au-Yeung G, Spillane AJ, Shannon KF, Gyorki DE, Hsiao E, Kapoor R, Thompson JR, Batula I, Howle J, Ch'ng S, Gonzalez M, Saw RPM, Pennington TE, Lo SN, Scolyer RA, Menzies AM. Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAFV600-mutant resectable melanoma: the randomized phase 2 NeoTrio trial. Nat Med. 2024 Sep;30(9):2540-2548. doi: 10.1038/s41591-024-03077-5. Epub 2024 Jun 21.","pmid":"38907159","type":"DERIVED"},{"citation":"Gorry C, McCullagh L, O'Donnell H, Barrett S, Schmitz S, Barry M, Curtin K, Beausang E, Barry R, Coyne I. Neoadjuvant treatment for stage III and IV cutaneous melanoma. Cochrane Database Syst Rev. 2023 Jan 17;1(1):CD012974. doi: 10.1002/14651858.CD012974.pub2.","pmid":"36648215","type":"DERIVED"}],"start_date":{"date":"2017-11-08","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma","url":"https://clinicaltrials.gov/study/NCT02858921"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/neotrio-nct02858921"}